PatentMay 4, 2026, 08:47 AM
Polyrizon expands patent claims for intranasal drug delivery platform
AI Summary
Polyrizon Ltd. announced the submission of amended claims for its U.S. patent application for its proprietary intranasal drug delivery platform. This expansion broadens the scope of protection to include drug delivery systems and methods of use, in addition to the core mucoadhesive composition. The company believes this will enhance the value and applicability of its platform by improving drug effectiveness through increased residence time and mucosal interaction, aligning with its strategy to strengthen its intellectual property portfolio.
Key Highlights
- Polyrizon submitted amended claims for its U.S. patent application for its intranasal drug delivery platform.
- The amended claims expand the scope of protection to include drug delivery systems and methods of use.
- The technology aims to enhance drug effectiveness by increasing residence time and ensuring close contact with mucosal tissues.
- Expanded claims cover compositions with sulfated polysaccharide polymers that form a uniform and continuous film.
- Key features include prolonged residence time, improved bioavailability, controlled film formation, and versatility.
- The platform has the potential to improve treatment outcomes across multiple therapeutic indications.
Price Impact
More from PLRZ